The Anifrolumab PRIM Program

Summary

Pregnancy and infant outcomes in anifrolumab exposed pregnancies using PRegnancy outcomes Intensive Monitoring (PRIM) data: The anifrolumab PRIM program

Eligibility

Inclusion Criteria:

* Currently or recently (within 1 year of pregnancy outcome) pregnant
* Exposure to at least 1 dose of anifrolumab at any time during pregnancy or in the 16 weeks prior to date of conception

Exclusion Criteria:

* Pregnancy cases that have been enrolled in the prospective pregnancy registry (D3461R00051), those reported prior to the start of the PRIM program, or those that have been exposed to known teratogens or investigational medications will be excluded from the anifrolumab PRIM study.

Conditions2

Interventions1

Related trials

• Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab. — AstraZeneca
• Anifrolumab Malignancy and Serious Infections Study — AstraZeneca
• Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus — AstraZeneca
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — AstraZeneca
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — AstraZeneca
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — AstraZeneca
• Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users — AstraZeneca

Browse More Trials